Side affects podcast

Who’s Really on Drugs?

Episode #44


A vast majority of Americans would agree that prescription drug prices are out of control. In fact, the cost of prescription drugs are rising at a faster pace than inflation (Source). And with the election season fast approaching, Ohio residents will have the opportunity to address the future of prescription drug prices in the state with their votes. In November, the Ohio Drug Price Relief Act will be making its way onto the Ohio ballot. Although it remains to be seen whether the act will pass or fail, the end results are guaranteed to have a major impact on the future of healthcare in Ohio. A recent poll by three television stations showed that the majority of voters are unclear about Issue 2 (Source). In this episode of Side Affects, Scott McGohan and Anne Marie Singleton are joined by McGohan Brabender employees, Michael Orr and Adam Griffith. Together, the four take a deeper dive into Issue 2 and discuss the potential ramifications this bill will create.

Subscribe on any of these platforms

Similar Episodes

Episode #26

“Hood Robin” and Prescription Drug Pricing

This episode marks our first foray into the secretive world of prescription drug pricing, and it's one we'll revisit many times. Scott likens it to Robin Hood in reverse — the real payers of prescriptions are propping up a dysfunctional system.

Listen Now

Episode #36

The Problem with PBMs

Scott and Anne Marie welcome guest Antonio Ciaccia of the Ohio Pharmacists Association to talk about high prescription drug prices. Ciaccia says a “dysfunctional system” allows a lack of transparency, and that makes it possible for middlemen within the pharmacy supply chain to negotiate high prices in secrecy.

Listen Now

Episode #40

The Ohio Drug Price Relief Act

Scott and Anne Marie welcome back Antonio Ciaccia of the Ohio Pharmacy Association to dissect Issue 2, the Ohio Drug Price Relief Act that was subsequently defeated in Ohio in November 2017. Learn why pharmacists believed the issue, which purported to lower drug prices, would have unintended consequences for consumers.

Listen Now